Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Eventide Asset Management

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 39
Average round size
info
The average size of a deal this fund participated in
$91M
Portfolio companies 27
Rounds per year 2.44
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.28
Exits 15
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science
Summary

The company was established in North America in United States. The main office of represented VC is situated in the Omaha.

We also calculated 3 valuable employees in our database.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Eventide Asset Management, startups are often financed by Third Rock Ventures, Wellcome Trust, The Column Group. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, EcoR1 Capital, TPG Biotech. In the next rounds fund is usually obtained by Zealand Pharma, TPG, Sofinnova Investments.

The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2019. Comparing to the other companies, this Eventide Asset Management performs on 15 percentage points more the average number of lead investments. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations.

We can highlight the next thriving fund investment areas, such as Medical Device, Health Diagnostics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Beta Bionics, Magenta Therapeutics, Karuna Therapeutics For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Eventide Asset Management:
Typical Co-investors
Eventide Asset Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Eventide Asset Management:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Affentranger Associates Switzerland, Zürich, Zurich
BCI Europe -
Caloga France, Ile-de-France, Paris
ChinaVest China, Shanghai
Creation Capital Austin, Texas, United States
DOEN Participaties Amsterdam, Noord-Holland, The Netherlands
Dongfang Economics Equity Investment Fund Management China, Guangdong, Shenzhen
Horizon Discovery Cambridge, Cambridgeshire, United Kingdom
LD Capital China, Shanghai, Shanghai
Mamadoo Ventures Gelderland, Netherlands, Rheden
ModusLink Global Solutions Massachusetts, United States, Waltham
Netflix California, Los Gatos, United States
PacifiCare Health Systems California, Cypress, United States
Shenyang Xunan Technology China, Liaoning, Shenyang
Sjova Gullbringusysla, Iceland, Reykjavík
Verus International New York, New York, United States
Vocap Ventures Atlanta, Georgia, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sudo Biosciences

Biopharma
$30M13 Feb 2024 Menlo Park, California, United States

Sudo Biosciences

Biopharma
$116M20 Dec 2023 Menlo Park, California, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$123M22 Mar 2023 Cambridge, Massachusetts, United States

Beta Bionics

Biotechnology
Diabetes
Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Shoreline Biosciences

Biotechnology
Life Science
Medical
$140M02 Nov 2021 San Diego, California, United States

DiCE Molecules

Biotechnology
Medical
Medical Device
$60M24 Aug 2021 California, United States

Kojin Therapeutics

Biopharma
Biotechnology
Life Science
Medical
$60M09 Jun 2021 Cambridge, Massachusetts, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$82M13 May 2021 Cambridge, Massachusetts, United States

Arch Oncology

Biotechnology
$105M27 Apr 2021 California, United States
News
DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Turnstone Biologics Raises $80 Million Series D Financing

– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Eventide Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 39
Average round size 91M
Rounds per year 2.44
Peak activity year 2020
Lead investments 4
Follow on index 0.28
Exits 15
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Sudo Biosciences

Biopharma
$30M13 Feb 2024 Menlo Park, California, United States

Sudo Biosciences

Biopharma
$116M20 Dec 2023 Menlo Park, California, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$123M22 Mar 2023 Cambridge, Massachusetts, United States

Beta Bionics

Biotechnology
Diabetes
Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Shoreline Biosciences

Biotechnology
Life Science
Medical
$140M02 Nov 2021 San Diego, California, United States

DiCE Molecules

Biotechnology
Medical
Medical Device
$60M24 Aug 2021 California, United States

Kojin Therapeutics

Biopharma
Biotechnology
Life Science
Medical
$60M09 Jun 2021 Cambridge, Massachusetts, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$82M13 May 2021 Cambridge, Massachusetts, United States

Arch Oncology

Biotechnology
$105M27 Apr 2021 California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: